Enlivex (ENLV) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enlivex is the larger company by market cap ($5.5 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ENLV | RDHL |
|---|---|---|
| Share price | $0.277 | $0.578 |
| Market cap | $5.51M | $5.14M |
| 1-day change | -10.85% | +21.94% |
| P/E ratio (TTM) | 0.00 | — |
| Forward P/E | — | 19.27 |
| EPS (TTM) | $494.00 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $2.14 |
| 52-week low | $0.2555 | $0.4351 |
| Distance from 52-week high | -98.98% | -72.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +28780.87% | — |
| Average volume | 440.07K | 1.81M |
| Shares outstanding | 19.91M | 8.89M |
| Employees | 34 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Healthcare · Biotechnology · 34 employees
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Healthcare · Drug Manufacturers - Specialty & Generic · 13 employees
ENLV vs RDHL FAQ
Which is bigger, Enlivex or Redhill Biopharma?
Enlivex (ENLV) is larger, with a market capitalization of $5.51M compared with $5.14M for Redhill Biopharma (RDHL).
Are Enlivex and Redhill Biopharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Enlivex and Drug Manufacturers - Specialty & Generic for Redhill Biopharma.